From EU Directives to Local Medicines Law: Where “The Rules” Really Come From (and why GMP splits for veterinary medicines in July 2026)

From EU Directives to Local Medicines Law: Where “The Rules” Really Come From (and why GMP splits for veterinary medicines in July 2026)

The rules that govern the manufacture, import and distribution (a.o.) of medicine consist of a relationship between binding EU legislation, practical guidance, and national (“local”) medicines law that actually powers inspections, licensing, and enforcement in each country. The confusion usually starts the moment someone poses the following: “The GMP guidelines are law”.

The real answer is that Europe runs on layered instruments, each designed to do a different job.

The hard law layer: EU Regulations and EU Directives

At the top sits EU legislation. But not all EU legislation works the same way.

A Regulation is meant to land as one unified rulebook across the Union. In the EU Treaties’ own wording, a regulation is “binding in its entirety and directly applicable in all Member States.” That “directly applicable” piece matters: in principle, a regulation does not need each country to rewrite it into a local act before it can apply. 

A Directive is different by design. It binds Member States “as to the result to be achieved,” while leaving national authorities’ choice over “form and methods.” In other words, directives harmonise what outcomes must be reached, but the how is implemented through local legislation. The directive (probably) most familiar to our readers is the 2001/83/EC governing medicinal products for human use.

That implementation step is usually called transposition: the process of incorporating directives into national law by a deadline. This is where the phrase “local medicinal law” becomes more than a formality. In every Member State, directives are translated into the country’s own legal structure: medicines acts, decrees, administrative rules, and the powers of national competent authorities. Even when two countries transpose the same directive, the operational reality can still differ: which authority handles which step, what portals and forms are used, what language requirements exist, and how penalties and enforcement are applied. In the Netherlands we use the “Geneesmiddelenwet” as the national law.

The guidance layer: not “law,” but often the thing inspectors expect

If directives and regulations are the legal backbone, then guidelines are the connective muscles. They turn broad legal requirements into something companies can operationalise: dossier formats, quality expectations, procedural timelines, and inspection ready interpretations.

The European Commission’s own Notice to Applicants framework (EudraLex Volume 2) is unusually explicit about what guidance is—and what it is not. The Commission states that the Notice “has no legal force” and that “in case of doubt… reference should be made to the appropriate Union Directives and Regulations.” 

That doesn’t make guidance optional in practice. It means guidance typically functions as:

• a shared interpretation of how authorities read the law,
• a harmonisation tool so applications and inspections don’t drift into 27 different styles (although a few countries tend to deviate far more often – and wider - than others),
• an efficient way for regulators to update expectations without rewriting primary legislation every time a scientific or operational detail evolves.

So, in the real world, companies treat guidance as “soft law” that strongly shapes regulatory outcomes, even while recognising that the enforceable legal basis sits in directives, regulations, and national implementing measures.

EudraLex

A lot of EU medicines guidance is organised through EudraLex, the Commission’s collection of volumes known as “The rules governing medicinal products in the European Union.” The Commission frames this relationship clearly: “The basic legislation is supported by a series of guidelines that are also published” in the EudraLex volumes. 

This is a helpful mental model: the legislation is the foundation, EudraLex is where much of the guidance is curated and maintained. And because guidance evolves, EudraLex evolves too, sometimes by updating volumes, sometimes by moving content to other websites, and sometimes by declaring older volumes obsolete.

Which brings us to a major upcoming change that will matter to anyone running a veterinary GMP quality system.

The July 2026 turning point: human vs. veterinary GMP formally separates

On its EudraLex overview page, the Commission warns that Volume IV applies to veterinary medicinal products only until 15 July 2026. 

The Volume IV page itself makes the transition even more concrete:

• Until 15/JUL/2026, Volume 4 GMP guidelines apply to both human and veterinary medicinal products. 
• From 16/JUL/2026 onwards, veterinary GMP will be governed by Commission Implementing Regulation (EU) 2025/2091 (GMP for veterinary medicinal products) and Commission Implementing Regulation (EU) 2025/2154 (GMP for active substances used as starting materials in veterinary medicinal products), both adopted in accordance with Regulation (EU) 2019/6. 

This change constitutes a legal and operational reorientation to a veterinary-specific GMP framework embedded in veterinary legislation under Regulation (EU) 2019/6.

EMA summarises the broader shift behind that regulation: Regulation (EU) 2019/6 updated EU rules on the authorisation and use of veterinary medicines and became applicable on 28 January 2022. The GMP split is part of the same trajectory: moving veterinary medicines into a more distinct and modernised regulatory architecture.

“Split” does not mean “divergence” in expectations

A reasonable fear is that separation automatically means fragmentation: two sectors, two rulebooks, two audit/inspection realities. The Commission’s own language is designed to prevent that fear from becoming a self-fulfilling prophecy. On the Volume 4 page, it states that despite different legal bases, the GMP requirements for veterinary medicinal products and their active substances will remain aligned with those for human medicines—and it even provides correspondence tables mapping the relationships. 

So the likely day-to-day impact is less about reinventing GMP principles and more about reframing:

• which legal text you cite in your PQS,
• what inspectors reference and how findings are justified,
• how training materials and supplier agreements are worded,
• how you demonstrate compliance when your portfolio crosses both human and veterinary products.

In short: many expectations may remain familiar, but the legal anchor you point to changes on 16 July 2026.

“Volumes 7, 8 and 9 no longer apply”: what that signals about guidance in the EU

The Commission’s EudraLex overview carries a second warning alongside the GMP change: 

“Please note that Volume 4 applies to veterinary medicinal products only until 15 July 2026, and Volumes 7, 8 and 9 no longer apply. More detailed explanations on the current status are provided on the respective pages for each volume. “

Read literally, that sounds like huge chunks of science and safety oversight have been deleted. In reality, it’s better read as a statement about where guidance now lives and which documents remain current references.

Take pharmacovigilance. The Commission’s Volume 9-page states plainly that Volume 9 “no longer applies.” It then explains what replaced it:

• For human medicines, older Commission pharmacovigilance guidance (Volume 9A) was replaced, with the application of new pharmacovigilance legislation from July 2012, by the EMA’s Good Pharmacovigilance Practices (GVP) guidelines. 
• For veterinary medicines, pharmacovigilance requirements are set in Regulation (EU) 2019/6, and the Commission established measures on veterinary good pharmacovigilance practice via Commission Implementing Regulation (EU) 2021/1281, complemented by EMA-developed veterinary guidance. 

Now look at residues and food safety. The Volume 8 page states that a dedicated guideline on maximum residue limits is no longer included in the Notice to Applicants, and it points readers to the regulations where that material is now maintained. 

And for veterinary scientific guidance, Volume 7 describes guidelines as a tool for practical harmonisation in how Member States and EMA interpret requirements for quality, safety, and efficacy—and it points users toward EMA scientific guidelines for more information. 

Put together, this is a pattern: EU medicines guidance is increasingly treated as a living system. Some “volumes” shrink, move, or become legacy references, while newer or more actively maintained guidance sits directly with EMA or inside implementing regulations that update faster and map more cleanly onto newer legislative frameworks.

So how do directives, guidelines, and local law interact in practice?

If you operate in multiple European countries, you can think of compliance as a three-way handshake:

EU law sets the baseline obligation. Regulations apply across the Union; directives define outcomes and are transposed into national law. 

Guidelines explain how to meet that baseline in a regulator-recognisable way. They rarely carry formal legal force on their own, and even the Commission’s Notice to Applicants stresses you should defer to the binding directives and regulations if there’s doubt. But guidance still shapes what “good enough” looks like in dossiers, audits, inspections, and lifecycle work.

Local medicinal law turns the framework into enforceable law. National competent authorities are the ones issuing licences, conducting inspections, imposing measures, and handling administrative processes. Even when the core requirement is EU-wide, the operational interface: forms, portals, local timelines, language expectations and inspection repetition timelines sits in the national layer.

What to do now about the July 2026 veterinary GMP change

Even if you expect alignment to remain high, the transition date creates real work. The organisations that feel least disruption tend to be the ones that treat 16 July 2026 as a documentation and governance milestone: updating controlled references, training internal auditors, validating templates, and ensuring supplier quality language matches the new veterinary legal anchors.

The key is not panic—it’s precision. The Commission has already told you the cutoff date, the replacement implementing regulations, and the intent to remain aligned with human GMP expectations. The opportunity is to use that clarity early, so the change lands as a controlled update rather than an inspection surprise.

This article is informational and not legal advice. For high-impact decisions (manufacturing authorisations, inspection strategy, enforcement exposure), validate interpretation with the relevant competent authority and/or specialised counsel in the target jurisdictions.